Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatoblastoma | 7 | 2024 | 179 | 2.660 |
Why?
|
| Liver Neoplasms | 8 | 2024 | 1314 | 1.970 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2024 | 74 | 1.620 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2024 | 930 | 1.380 |
Why?
|
| Neuroblastoma | 11 | 2019 | 526 | 1.290 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2019 | 541 | 0.960 |
Why?
|
| Indocyanine Green | 1 | 2024 | 55 | 0.870 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 3 | 2019 | 145 | 0.750 |
Why?
|
| Oxadiazoles | 1 | 2021 | 25 | 0.720 |
Why?
|
| Cell Line, Tumor | 14 | 2024 | 3348 | 0.650 |
Why?
|
| Neovascularization, Pathologic | 2 | 2017 | 240 | 0.640 |
Why?
|
| Piperazines | 1 | 2021 | 240 | 0.630 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2024 | 889 | 0.610 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2017 | 60 | 0.570 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 546 | 0.560 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 376 | 0.540 |
Why?
|
| Apoptosis | 11 | 2021 | 1806 | 0.540 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 657 | 0.530 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 723 | 0.520 |
Why?
|
| Neurofibromin 1 | 1 | 2016 | 41 | 0.500 |
Why?
|
| MAP Kinase Signaling System | 3 | 2017 | 314 | 0.500 |
Why?
|
| Benzimidazoles | 1 | 2016 | 133 | 0.470 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 3 | 2013 | 19 | 0.460 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 1893 | 0.430 |
Why?
|
| STAT Transcription Factors | 1 | 2013 | 23 | 0.410 |
Why?
|
| Janus Kinases | 1 | 2013 | 31 | 0.410 |
Why?
|
| Signal Transduction | 11 | 2021 | 4536 | 0.410 |
Why?
|
| Doxorubicin | 6 | 2019 | 290 | 0.400 |
Why?
|
| Cell Proliferation | 8 | 2019 | 2312 | 0.370 |
Why?
|
| Up-Regulation | 3 | 2021 | 868 | 0.350 |
Why?
|
| Heterografts | 2 | 2024 | 173 | 0.350 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 618 | 0.320 |
Why?
|
| Mice | 12 | 2024 | 17637 | 0.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 1254 | 0.300 |
Why?
|
| Animals | 18 | 2024 | 34238 | 0.290 |
Why?
|
| Pyrimidines | 2 | 2024 | 373 | 0.270 |
Why?
|
| Quinazolines | 2 | 2019 | 175 | 0.270 |
Why?
|
| Liver | 2 | 2024 | 1746 | 0.240 |
Why?
|
| Pyridazines | 2 | 2016 | 51 | 0.240 |
Why?
|
| Gene Knockdown Techniques | 3 | 2021 | 359 | 0.240 |
Why?
|
| Cyclopentanes | 1 | 2024 | 20 | 0.230 |
Why?
|
| Liquid Biopsy | 1 | 2024 | 14 | 0.230 |
Why?
|
| Coloring Agents | 1 | 2024 | 77 | 0.220 |
Why?
|
| Ki-67 Antigen | 1 | 2024 | 113 | 0.220 |
Why?
|
| Tumor Burden | 3 | 2019 | 230 | 0.200 |
Why?
|
| Dependovirus | 1 | 2024 | 128 | 0.200 |
Why?
|
| Humans | 23 | 2024 | 125195 | 0.200 |
Why?
|
| Receptors, Notch | 3 | 2013 | 201 | 0.190 |
Why?
|
| Mice, Nude | 6 | 2019 | 708 | 0.190 |
Why?
|
| Hep G2 Cells | 2 | 2018 | 85 | 0.180 |
Why?
|
| N-Myc Proto-Oncogene Protein | 2 | 2019 | 55 | 0.180 |
Why?
|
| Child, Preschool | 5 | 2024 | 14022 | 0.180 |
Why?
|
| Cell Survival | 6 | 2019 | 813 | 0.170 |
Why?
|
| Drug Synergism | 5 | 2019 | 229 | 0.170 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2019 | 128 | 0.170 |
Why?
|
| Piperidones | 1 | 2019 | 7 | 0.160 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2019 | 61 | 0.160 |
Why?
|
| Phenylurea Compounds | 1 | 2019 | 49 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1696 | 0.150 |
Why?
|
| Child | 6 | 2024 | 24407 | 0.150 |
Why?
|
| Zearalenone | 1 | 2017 | 4 | 0.140 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2017 | 45 | 0.140 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 286 | 0.140 |
Why?
|
| Carbazoles | 1 | 2017 | 33 | 0.140 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2015 | 67 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2017 | 12 | 0.140 |
Why?
|
| Aniline Compounds | 1 | 2017 | 18 | 0.140 |
Why?
|
| Nifurtimox | 1 | 2016 | 3 | 0.130 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 128 | 0.130 |
Why?
|
| Mice, SCID | 1 | 2017 | 569 | 0.130 |
Why?
|
| src-Family Kinases | 1 | 2017 | 90 | 0.130 |
Why?
|
| Buthionine Sulfoximine | 1 | 2016 | 28 | 0.130 |
Why?
|
| Drosophila Proteins | 3 | 2012 | 714 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 1694 | 0.130 |
Why?
|
| Epidermal Growth Factor | 1 | 2017 | 123 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2024 | 1497 | 0.130 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2016 | 15 | 0.130 |
Why?
|
| Quinolines | 1 | 2017 | 98 | 0.130 |
Why?
|
| Nitriles | 1 | 2017 | 146 | 0.130 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2016 | 144 | 0.130 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 376 | 0.120 |
Why?
|
| Anilides | 1 | 2015 | 49 | 0.120 |
Why?
|
| Piperidines | 1 | 2017 | 208 | 0.120 |
Why?
|
| Disease Models, Animal | 2 | 2024 | 4395 | 0.120 |
Why?
|
| Imidazoles | 1 | 2016 | 203 | 0.120 |
Why?
|
| ras Proteins | 1 | 2016 | 137 | 0.120 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 206 | 0.110 |
Why?
|
| Protein Transport | 2 | 2013 | 368 | 0.110 |
Why?
|
| Pyridines | 1 | 2015 | 230 | 0.110 |
Why?
|
| Female | 10 | 2024 | 66803 | 0.110 |
Why?
|
| Infant | 3 | 2024 | 12507 | 0.110 |
Why?
|
| Drosophila | 3 | 2013 | 774 | 0.110 |
Why?
|
| Cell Movement | 1 | 2016 | 847 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2021 | 4821 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 668 | 0.090 |
Why?
|
| Mutation | 5 | 2022 | 5842 | 0.090 |
Why?
|
| Male | 4 | 2024 | 61524 | 0.080 |
Why?
|
| Neoplasms | 1 | 2024 | 2794 | 0.080 |
Why?
|
| Adolescent | 2 | 2024 | 19355 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2017 | 3157 | 0.080 |
Why?
|
| Trans-Activators | 1 | 2012 | 799 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1142 | 0.070 |
Why?
|
| Vesicular Transport Proteins | 1 | 2009 | 120 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2024 | 725 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2017 | 77 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 1266 | 0.060 |
Why?
|
| NEDD8 Protein | 1 | 2024 | 11 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 1 | 2024 | 163 | 0.060 |
Why?
|
| Hydroxamic Acids | 1 | 2024 | 56 | 0.050 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2024 | 75 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2009 | 1021 | 0.050 |
Why?
|
| Drosophila melanogaster | 1 | 2009 | 769 | 0.050 |
Why?
|
| Vincristine | 1 | 2024 | 193 | 0.050 |
Why?
|
| Hepatocytes | 1 | 2024 | 209 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 2397 | 0.050 |
Why?
|
| Recurrence | 1 | 2023 | 1420 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2024 | 687 | 0.040 |
Why?
|
| Protein Unfolding | 1 | 2019 | 10 | 0.040 |
Why?
|
| Young Adult | 2 | 2024 | 9056 | 0.040 |
Why?
|
| Chromosome Aberrations | 1 | 2022 | 613 | 0.040 |
Why?
|
| Etoposide | 1 | 2019 | 115 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 101 | 0.040 |
Why?
|
| Cyclin D1 | 1 | 2018 | 112 | 0.040 |
Why?
|
| Ubiquitination | 2 | 2009 | 167 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 196 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2017 | 25 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2017 | 25 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 898 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2019 | 735 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2015 | 23 | 0.030 |
Why?
|
| Isotretinoin | 1 | 2015 | 26 | 0.030 |
Why?
|
| Topotecan | 1 | 2015 | 48 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2017 | 281 | 0.030 |
Why?
|
| Dacarbazine | 1 | 2015 | 95 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2017 | 459 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2016 | 1064 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 429 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 24 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 489 | 0.030 |
Why?
|
| Prognosis | 1 | 2023 | 4641 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2017 | 237 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2023 | 12396 | 0.030 |
Why?
|
| Phenotype | 2 | 2017 | 4263 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 1102 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 684 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2015 | 293 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2012 | 48 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2016 | 1631 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 2564 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5176 | 0.020 |
Why?
|
| Endosomes | 1 | 2009 | 64 | 0.020 |
Why?
|
| Oogenesis | 1 | 2009 | 56 | 0.020 |
Why?
|
| Genes, Insect | 1 | 2009 | 123 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 1695 | 0.020 |
Why?
|
| Caspases | 1 | 2009 | 162 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 2636 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 6336 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 558 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2009 | 760 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2023 | 16344 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 10312 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2009 | 1527 | 0.010 |
Why?
|